Rhabdosia rubescens

Rabdosia rubescens (Isodon rubescens): A Comprehensive Reference

1. Identity and Botanical Classification

Rabdosia rubescens is a perennial herbaceous plant in the family Lamiaceae, mainly found in central and southern China. Its currently accepted scientific name in modern botanical taxonomy is Isodon rubescens (Hemsl.) H. Hara, though the name Rabdosia rubescens remains widely used in the pharmacological and dietary supplement literature. The genus Isodon (Lamiaceae family) consists of more than 150 species of perennial herbs that are widely distributed in tropical Africa, tropical and subtropical Asia, and East Central Siberia, with a few species in Malaysia, Australia, and the Pacific Islands. There are 90 species and 21 varieties in China, among which the largest number of species is found in the Southwest provinces.

I. rubescens is also known as Rabdosia rubescens var. lushiensis, I. rubescens var. eglandulosus, Rabdosia rubescens var. taihangensis, and Rabdosia dichromophylla, as well as under local names such as "Donglingcao," "Binglingcao," "Xuehuacao," "Poxuedan," "Shanxiangcao," "Yehuoxiang," and "Liuyueling" in China. In pinyin transliteration, the most common name used in the supplement industry is Dong Ling Cao. Rabdosia rubescens, also known by names including "Blood-breaking Pill" and "Ice Sweet," belongs to the genus Isodon of the Labiatae family. It is widely distributed in the Yellow River and Yangtze River basins, with the main producing area being Jiyuan, Henan Province, China.

Common Forms and Preparations

Not only is it a source of traditional Chinese medicine, but it is also a raw material for chemical drugs, as well as a tea beverage for daily consumption. The leaves of Rabdosia rubescens are still used for tea in China for their antibacterial function. Available commercial forms include dried aerial plant parts (loose herb), standardized aqueous or ethanol extract powders, tablets (known in China as Donglingcao Pian), capsules, and prepared decoctions. The plant is sold in Western markets primarily as a root extract or aerial part extract, often standardized to oridonin content. In 1991, the Ministry of Health of China approved the dried leaves and aboveground parts of Rabdosia rubescens as Chinese medicinal materials, which were included in the standards for Chinese medicinal materials issued by the Ministry of Health.

2. Traditional and Historical Use

I. rubescens was first recorded in the Jiuhuang Bencao (救荒本草) compiled by Zhu Xun in the Ming Dynasty (A.D. 1368–1644), where it was often used as a wild vegetable in ancient China. The first known record of I. rubescens is found in Jiuhuang Bencao (Ming Dynasty, A.D. 1406), which is an encyclopedia that specializes in endemic plants and combines edible aspects with famine relief.

Isodon rubescens is a medicinal and food plant, often eaten as a wild vegetable in ancient China, and has been widely used for decades to treat sore throats, tonsillitis, colds and headaches, bronchitis, chronic hepatitis, joint rheumatism, snake and insect bites, and various cancers. The aboveground parts of I. rubescens are commonly used in traditional Chinese medicine (TCM) for sore throats, tonsillitis, laryngothralgia, colds, headaches, fever, heating, choking, nausea, tracheitis, chronic hepatitis, joint rheumatism, and snake and insect bites.

In TCM prescription, I. rubescens is characterized as sweet and bitter, and slightly cold in its action on the body; it is understood to clear away heat and has detoxifying, anti-inflammatory, analgesic, and antitumor effects. In the Chinese Pharmacopoeia 2020 edition, I. rubescens is described as sweet and bitter in prescription and slightly cold after acting on the body, acting on the lung, stomach, and liver meridian, with the effects of clearing away heat, detoxification, activating blood and relieving pain.

Traditional Chinese therapeutic actions attributed to Dong Ling Cao include: clear heat and remove toxicity, activate blood and stop bleeding.

As a traditional Chinese herb, Rabdosia rubescens was first used as an anti-inflammation herb for sore throat and tonsillitis, and has been included in the Chinese Pharmacopoeia since 1977. It has been used in the treatment of esophageal cancer in Henan Province, China, for more than 50 years. It is also used alone or in combination with other herbs to treat cardiac cancer, liver cancer, lung cancer, prostate cancer, and bladder cancer in TCM. Since 1977, the standard extract of this herb has also been developed as a drug product for treating sore throats and inflammation in China.

I. rubescens is recorded in various versions of the Chinese Pharmacopoeia. Several registered Chinese drug products have been formulated around the plant, including Donglingcao Pian (tablets) indicated for tonsillitis and pharyngitis, and Donglingcao tea indicated for pharyngitis and cancer prevention.

3. Key Constituents and Active Compounds

Overview of Phytochemistry

Rabdosia rubescens extract (RRE) contains terpenoids and flavonoids, but the most active ingredient within the extract attributed to the inhibition of cancer is the kaurene diterpene, oridonin.

Among the bioactive constituents, oridonin, ponicidin, lushanrubescensin H, lushanrubescensin J, rabdosin A, isodocarpin, rabdoternin F, shikokianin, lasiodin, parvifoline AA, lasiodonin, lasiodoninacetonide, rosthorin, isojiangrubesin C, isojiangrubesin E, rabdoternin E, 11-O-acetylangustifolin, jaridonin, 14-O-acetyl-oridonin, isodonoiol, isodonal, rabdosin B, effusanin A, xerophinoid B, and 7,14-O-(1-methylethylidene) oridonin are best known for their antitumor, antioxidant, anti-inflammatory, antibacterial, anti-cardiovascular, anti-dementia, and immune regulatory activities.

Oridonin

Oridonin is the primary bioactive compound and the most extensively researched constituent of R. rubescens. Oridonin (PubChem CID: 5321010, CAS No: 28957-04-2, MW: 364.4 g/mol), with the molecular formula C₂₀H₂₈O₆, is a naturally occurring terpenoid that mainly exists in Isodon rubescens. Oridonin is an ent-kaurane diterpenoid compound isolated from the traditional Chinese herb Rabdosia rubescens that has shown various pharmacological and physiological effects such as anti-tumor, anti-bacterial, and anti-inflammatory properties. In 1977, the diterpene compound oridonin was discovered, recognized for its diverse biological activities and regarded as the second most bioactive compound in the plant, after subsequent research identified further compounds.

Ponicidin

Ponicidin is the second major ent-kaurane diterpenoid of the plant. Both oridonin and ponicidin are ent-kaurane diterpenoids, extracted from Isodon rubescens, a plant that is well known in Traditional Chinese Medicine. In pancreatic cancer, oridonin induces apoptosis and leads to an arrest in the G2/M-phase of the cell cycle; ponicidin is also known to induce apoptosis.

Jaridonin and Other Diterpenoids

A novel ent-kaurene diterpenoid named jaridonin was isolated from Isodon rubescens ("Donglingcao" in Chinese), which is a perennial herb of the Isodon genus belonging to the Labiatae family. Triterpenes and their derivatives are well-known in the research of natural phytochemistry for their excellent antitumor activity.

Other Compound Classes

Rabdosia rubescens extract (RRE) contains terpenoids and flavonoids, but the most active ingredient within the extract attributed to the inhibition of cancer is the kaurene diterpene, oridonin. Additional compound classes identified in the plant include steroids, volatile oils, polysaccharides, and organic acids. Analyses of individual herbs comprising PC-SPES (of which Rabdosia rubescens was one component) reveal the presence of numerous bioactive compounds including phytoestrogens, flavonoids, alkaloids, triterpenes, polysaccharides, and trace elements.

4. Mechanisms of Action

Anti-inflammatory Mechanisms

The anti-inflammatory effect of oridonin is primarily associated with suppressing the nuclear factor-kappa B (NF-κB) signaling pathway, reducing secretion of serum cytokines including interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α), and inhibiting expression and function of toll-like receptors 4 (TLR4) as well as the p38-mitogen activated protein kinase (p38-MAPK) in endometritis, diabetic nephropathy, vascular inflammation, acute lung injury, liver injury, inflammatory bowel disease, and sepsis.

A mechanistically significant discovery was the identification of oridonin as a direct covalent inhibitor of the NLRP3 inflammasome. Oridonin was reported to inhibit NLRP3, which is a key component in the NLRP3 inflammasome, by targeting the Cys279 residue of NLRP3 in the NACHT domain. Oridonin has been reported to inhibit NF-κB or MAPK activation to suppress the release of proinflammatory cytokines, such as tumor necrosis factor (TNF)-α and interleukin (IL)-6.

Anticancer Mechanisms

Oridonin inhibits tumor cell proliferation and induces cancer cell death by regulating a series of transcription factors, protein kinases as well as pro- and/or anti-apoptotic proteins. Multiple upstream and downstream pathways have been identified:

• Apoptosis induction: Oridonin-mediated apoptosis involves multiple proteins and pathways, such as protein kinase B (AKT), the nuclear factor-kappa B (NF-κB) and mitochondrial redox signaling pathway.
• AML1-ETO targeting: Oridonin targets the acute myeloid leukemia-associated fusion protein (AML1-ETO), an oncoprotein enhancing self-renewal of hematopoietic stem/progenitor cells that blocks hematopoietic differentiation. The AML1-ETO protein recruits nuclear receptor co-repressor (NCoR) histone deacetylase (HDAC) complex, inhibiting transcription of AML1 target genes.
• PI3K/AKT pathway: Oridonin selectively impaired the growth of human breast cancer cells with hyperactivation of AKT signaling (p-AKT^High) in vitro and in vivo.
• Reactive oxygen species and glutathione depletion: Oridonin significantly increases the production of reactive oxygen species (ROS) in esophageal squamous carcinoma cell lines, and can dramatically reduce intracellular glutathione (GSH) levels in a concentration- and time-dependent manner.
• Antiangiogenesis: Bioassay-guided fractionation using a novel in vitro human endothelial cell-based assay for angiogenesis afforded the diterpenoids ponicidin and oridonin, with significant antiangiogenic activity at subcytotoxic concentrations.
• Cell cycle arrest: Both oridonin and ponicidin exhibit antitumor effects by inducing tumor cell apoptosis and autophagy and inhibiting tumor cell proliferation.
• PPAR-γ activation: Oridonin exerted a dramatic pro-apoptotic effect by activating PPAR-γ and inhibiting the Nrf2 pathway in vitro and in vivo.
• EMT inhibition: Oridonin significantly inhibited migration and invasion of human nasopharyngeal carcinoma cell lines, and increased the expression of E-Cadherin while decreasing the expressions of vimentin and twist1 at the mRNA and protein levels in a dose-dependent manner.

Synergy of Whole Extract vs. Isolated Compound

Rabdosia rubescens is a herbal root extract of TCM used to treat inflammatory diseases and oral cancers. A key principle of TCM is that multiple ingredients in a plant extract are more effective and less toxic than a single purified active ingredient or a purified drug derived from a plant product. In order to research synergy with a complete plant extract, the effects of RRE on the inhibition of prostate cancer cell proliferation were compared to the effects of pure oridonin alone in vitro. The genomic and in vivo evidence from this 2012 study (published in Experimental and Therapeutic Medicine) identified gene expression targets activated by the whole extract that were not activated by oridonin alone, providing molecular evidence for the synergistic action of the complete extract.

5. Scientific Evidence by Area of Use

5.1 Cancer — Esophageal Carcinoma

The herb has been used as a folk, botanical medicine for the treatment of cancer, especially esophageal cancer, and inflammatory disease by local people in Henan Province, China. The strongest concentration of clinical interest, and the longest traditional use in an oncological context, relates to esophageal squamous cell carcinoma (ESCC).

Rabdosia rubescens and its extracts were shown to suppress disease progression, reduce tumor burden, and prolong survival in patients with esophageal cancer, gastric carcinoma, or liver cancer — a claim originating from historical clinical reports in China, the details of which remain incompletely characterized in peer-reviewed literature available in English.

At the cellular and molecular level, oridonin was shown to inhibit proliferation and induce apoptosis in the human oesophageal squamous cell carcinoma cell line EC9706, in vitro. Oridonin showed selective cytotoxicity to esophageal squamous carcinoma cells with p53 mutation, since mutant-p53 cells had lower SLC7A11 expression, a component of the cystine/glutamate antiporter. Rabdosia rubescens has been demonstrated to be effective against ESCC; network pharmacology analysis revealed that CCNA2, TOP2A, AURKA, CCNB2, CDK2, CHEK1, and other potential central targets are therapeutic targets for RR treatment of ESCC.

Evidence strength: The bulk of evidence in ESCC is preclinical (in vitro cell lines and animal models). Large-scale, randomized controlled clinical trials in ESCC are lacking. Future studies should undergo ethical review and include larger-scale randomized controlled trials to validate the efficacy of R. rubescens in treating tumors, thereby promoting its role as an anti-tumor traditional Chinese medicine.

5.2 Cancer — Prostate Cancer and the PC-SPES Formulation

Rabdosia rubescens attracted significant attention in Western oncology primarily as a component of PC-SPES, a commercially marketed eight-herb dietary supplement. PC-SPES is an herbal combination used by patients with prostate cancer that consists of eight herbs: chrysanthemum, isatis, licorice, Ganoderma lucidum, Panax pseudo-ginseng, Rabdosia rubescens, saw palmetto, and scutellaria (skullcap).

Clinical trials suggested that PC-SPES lowers PSA (prostate specific antigen) and testosterone levels in humans and has some anticancer effects. A Phase II trial of 33 patients with androgen-dependent prostate cancer and 37 patients with androgen-independent prostate cancer assessed the efficacy and toxicity of PC-SPES in a prospective fashion. However, PC-SPES was taken off the market because some batches were found to contain prescription medicines in addition to the herbs. It is not known if the clinical results were caused by the herbs in PC-SPES, prescription medicines that were found in the mixture, or both. This contamination issue fundamentally confounds interpretation of all PC-SPES clinical data as it pertains to Rabdosia rubescens specifically.

Regarding the individual contribution of R. rubescens to PC-SPES's activity: antiangiogenic activity was identified in an aqueous ethanol extract of Rabdosia rubescens, a component of PC-SPES; bioassay-guided fractionation afforded the diterpenoids ponicidin and oridonin, with significant antiangiogenic activity at subcytotoxic concentrations, suggesting that these constituents may strongly contribute to the demonstrated clinical efficacy of PC-SPES as a treatment for advanced prostate cancer. This is in vitro evidence only.

The botanical rabdosia rubescens (Isodon rubescens)—Chinese name dong ling cao—has two very active agents, oridonin and rubesencin B. Oridonin inhibits DNA synthesis in vitro, and rubesencin B inhibited cell growth in cancer cell lines in vitro and in a mouse model. (NCI PDQ monograph)

Evidence strength: The clinical evidence for Rabdosia rubescens alone in prostate cancer is absent; clinical data only exists in the context of the multi-herb PC-SPES formulation, which was adulterated. In vitro and animal data for individual constituents (oridonin, ponicidin) are substantial but cannot be extrapolated to clinical use without further trials.

5.3 Cancer — Broad-Spectrum Preclinical Activity

Oridonin, a major diterpenoid component of leaf extracts from Rabdosia rubescens, has been demonstrated to be effective against a variety of cancers, such as esophageal, leukemia, lung, pancreatic, prostate, breast, and colon, both in vivo and in vitro. Both pharmacological experiments and clinical trials have demonstrated that oridonin has significant activity against a wide variety of cancer cells including those from prostate, breast, non-small cell lung cancers, acute promyelocytic leukemia, and glioblastoma multiforme; it has been used for the treatment of human cancers, especially esophageal carcinoma and prostate carcinoma. Notably, the reference to "clinical trials" here is drawn from a ScienceDirect source and may reflect Chinese-language clinical observations rather than fully described randomized trials; the existing English-language peer-reviewed record does not contain published phase II/III RCT data for oridonin as a monotherapy.

Given its traditional and modern uses, active anti-tumor components, and mechanisms, R. rubescens is a promising resource in traditional Chinese medicine for anti-tumor therapy. To realize its full potential, future research should explore additional active anti-tumor compounds beyond oridonin and ponicidin.

5.4 Cancer — Pancreatic Cancer (In Vitro)

The diterpenoids oridonin and ponicidin are both extracts from Isodon rubescens, a plant used in Traditional Chinese Medicine that is known for its anti-inflammatory and antitumor properties in the treatment of esophageal and cardiac cancer. Researchers analyzed radiomodulating effects of oridonin and ponicidin in pancreatic cancer in vitro. Pancreatic cancer cell lines AsPC-1, BxPC-3, Panc-1, and MIA PaCa-2 were pretreated with oridonin or ponicidin and irradiated with 2 Gy to 6 Gy; long-term survival was determined by clonogenic assay, and cell cycle effects and intensity of γH2AX as indicator for DNA double-strand breaks were investigated by flow cytometry. This remains strictly in vitro evidence.

5.5 Inflammation

Besides their antitumor activity, Rabdosia rubescens and oridonin have also possessed anti-inflammatory activity. In China, Rabdosia rubescens is a commonly available over-the-counter (OTC) herbal medicine for the treatment of inflammatory diseases.

A mechanistically notable finding was published in Nature Communications (2018), establishing oridonin as a covalent inhibitor of the NLRP3 inflammasome. This discovery was significant because oridonin was reported to inhibit NLRP3, a key component in the NLRP3 inflammasome, by targeting the Cys279 residue of NLRP3 in the NACHT domain — a specific molecular target with direct therapeutic relevance across numerous inflammatory diseases. The findings suggest that NLRP3 is a direct target for oridonin-mediated anti-inflammatory actions in injured bronchial epithelial cells. Therefore, oridonin may be a novel therapy against NLRP3-related disorders, including pediatric asthma.

Evidence strength: Anti-inflammatory evidence is predominantly from in vitro and animal models; no large-scale human clinical trials of R. rubescens extract or oridonin for inflammatory conditions have been published in the peer-reviewed English literature as of the sources reviewed.

5.6 Liver — Alcohol-Induced Liver Damage

A recent study examined Rabdosia rubescens in the context of alcohol-induced liver disease (ALD). Based on the excellent effects of Rabdosia rubescens in regulating lipid metabolism and autophagy, researchers investigated its protective potential in ALD mouse models. This was a preclinical investigation. Hepatoprotective effects of oridonin have been studied as well: oridonin, a covalent NLRP3-inflammasome inhibitor, was found to ameliorate acetaminophen-induced acute liver injury; the study found that oridonin decreased hepatic cytochrome P450 2E1 level and increased glutathione content to prevent APAP metabolism, and then reduced the necrotic area, improved liver function, and inhibited APAP-induced proinflammatory cytokines and oxidative stress. These are rodent model studies only.

5.7 Oral Health — Gingivitis

Regarding a mild form of gum disease (gingivitis), early research shows that taking Rabdosia rubescens might reduce symptoms of gingivitis, such as red and bleeding gums. This evidence is characterized as preliminary and cannot support definitive conclusions.

5.8 Respiratory — Asthma (In Vitro)

A study evaluated the effects of oridonin on proliferation, inflammation, and apoptosis in interleukin-4 (IL-4)-stimulated human bronchial epithelial (16HBE) cells. Proliferation was assessed using a BrdU assay, while apoptosis-related proteins including ASC, cleaved caspase-1, and NLRP3 were detected with western blot. The results established that IL-4 stimulation markedly decreased proliferation of 16HBE cells, while administration of oridonin increased their proliferation. This is entirely in vitro evidence using an artificial asthma cell model.

5.9 Neurology — Cerebral Ischemia/Reperfusion (Preclinical)

Animal studies have examined oridonin in models of cerebral ischemia/reperfusion injury, with the primary mechanism attributed to inhibition of the NLRP3 inflammasome and NF-κB pathway. These are rodent model findings only and have not been evaluated in human clinical trials.

6. Body Systems and Health Areas of Association

Based on the peer-reviewed literature, Rabdosia rubescens and its constituents have been studied in connection with the following body systems and conditions. The level of evidence varies substantially across these areas:

• Oncology: Esophageal cancer (historically used; preclinical and limited clinical observation), prostate cancer (in context of PC-SPES multi-herb formula; clinical data confounded by contamination), leukemia, lung cancer, breast cancer, pancreatic cancer, colon cancer, liver cancer, gastric cancer (all predominantly preclinical).
• Immune and inflammatory systems: NF-κB-mediated inflammation, NLRP3 inflammasome activation, sepsis (animal models), inflammatory bowel disease (animal models).
• Respiratory system: Sore throat, tonsillitis, and tracheitis (traditional use, with some registered Chinese drug products); asthma (in vitro only).
• Hepatic system: Chronic hepatitis (traditional use), alcohol-induced liver damage (animal model), acetaminophen-induced liver injury (animal model).
• Oral health: Gingivitis (preliminary human data).
• Cardiovascular and cerebrovascular: Cerebral ischemia (animal models), vascular inflammation (in vitro/animal).
• Metabolic: Diabetic nephropathy and renal fibrosis (animal models via TXNIP/NLRP3 pathway inhibition).
• Musculoskeletal: Joint rheumatism (traditional use).

It has been proven to play a role in treating major diseases such as multiple cancers, leukemia, liver and kidney function impairment, and cardiovascular and cerebrovascular diseases — though this characterization in the bibliometric literature reflects the scope of research topics investigated, not established clinical efficacy in all areas.

7. Dosage Forms and Reported Dosages

No universally agreed-upon standardized dosage for Rabdosia rubescens or isolated oridonin has been established in Western regulatory guidance. Dosage information comes from Chinese pharmacopoeial standards, registered drug products, and individual studies.

• Chinese Pharmacopoeia / Traditional Use: The plant is used in decoction and as a tea. The leaves of Rabdosia rubescens are used for tea in China for their antibacterial function.
• Registered Chinese drug products: Donglingcao Pian (tablets) and related oral preparations are marketed and regulated in China for specific indications such as tonsillitis and pharyngitis, though specific dosing details from the original Chinese-language monographs are not fully represented in the English-language sources reviewed here.
• PC-SPES: A Phase II trial of 33 patients with androgen-dependent prostate cancer and 37 patients with androgen-independent prostate cancer assessed the efficacy and toxicity of PC-SPES — in that formulation, Rabdosia rubescens was one of eight herbs, and its individual dose within the capsules was not separately characterized in the published data.
• Oridonin (experimental): In vitro studies have used oridonin across a range of micromolar concentrations to assess cytotoxicity in cancer cell lines. Specific in vivo dosages used in animal models vary widely by study and route of administration. No approved dosage for isolated oridonin as a pharmaceutical exists in the Western regulatory framework.

Several lines of evidence indicated that oridonin may exhibit adverse effects, even toxicity under specific circumstances. Future research directions should emphasize investigating the interrelationship between concentration and pharmacological effects as well as toxicity, reducing pharmacological toxicity, and modifying the structure of oridonin—one of the pivotal approaches to strengthen pharmacological activity and bioavailability.

8. Safety Considerations and Drug Interactions

General Safety Profile

Generally speaking, there are few adverse reports on the safety of oridonin, but the lack of reports does not mean that there are no such potential risks. It is particularly important to explore the mechanisms responsible for the adverse risk of oridonin under particular circumstances.

Although oridonin has been proved to possess assorted pharmacological activities in vivo and in vitro, the specific mechanism of its biological activity has not been fully expounded. It has shown prominent adverse effects, even toxicity under specific circumstances in vitro and in vivo.

Hepatotoxicity Risk

Reports of hepatotoxicity in relation to high doses or prolonged administration in a few experimental models suggest that dose optimization and comprehensive safety evaluation are essential prior to therapeutic application.

Drug Interactions — CYP Enzyme System

Oridonin may affect CYP2C and CYP3A encoding enzymes in the body, which brings to light potential pharmacokinetic interactions with co-administered drugs that may use these CYP2C and CYP3A pathways. This consideration needs to be further pursued in the context of polypharmacy. Rabdosia rubescens might increase how quickly the liver breaks down some medications; taking Rabdosia rubescens along with some medications that are changed by the liver might decrease the effects of these medications.

Pregnancy and Lactation

There isn't enough reliable information to know if Rabdosia rubescens is safe to use when pregnant or breast-feeding.

Bioavailability Limitations

A significant pharmacological limitation of oridonin is poor aqueous solubility, which affects bioavailability. Research into formulation strategies — including nanosuspensions and structural analogs — is ongoing. Oridonin (ORI) is poorly soluble in water; it is a natural ent-kaurane diterpenoid extracted from different plants such as Isodon trichocarpus, Isodon japonicus, and Isodon shikokianus, and has various pharmacological and physiological effects including anti-inflammation, anti-bacterial, and anti-tumor activity.

The PC-SPES Contamination Precedent

PC-SPES was taken off the market because some batches were found to contain prescription medicines in addition to the herbs, and clinical trials of PC-SPES that were underway were stopped. This episode serves as a relevant historical safety case study for supplement products containing Rabdosia rubescens, underscoring the importance of product quality assurance when the herb is used in multi-ingredient formulations.

Need for Further Safety Research

Detailed toxicological assessments, dose–response investigations, and studies evaluating CYP-mediated metabolic interactions are essential to fully define the safety profile and support clinical translation. The overall safety data for R. rubescens as a whole-plant preparation in humans remains substantially underdeveloped in the peer-reviewed English-language literature.

9. Evidence Quality Summary

The weight of published research on Rabdosia rubescens and its primary active compound oridonin is heavily concentrated in preclinical (in vitro and animal) studies. Oridonin has shown considerable anticancer activities, which include cell cycle arrest, apoptosis induction, and angiogenesis suppression, but the relatively moderate potency and imprecise mechanisms of action have greatly hindered its clinical applications for the treatment of cancer. The 2024 systematic review published in the Journal of Ethnopharmacology (Rabdosia rubescens: A potent anti-tumor herbal remedy) noted that future studies should undergo ethical review and include larger-scale randomized controlled trials to validate the efficacy of R. rubescens in treating tumors, thereby promoting its role as an anti-tumor traditional Chinese medicine.

The 2022 comprehensive review in Frontiers in Pharmacology similarly characterized the scientific body of knowledge as requiring further high-quality clinical investigation. The comprehensive and systematic review of the ethnomedicinal uses, phytochemical composition, pharmacological activity, quality control, and toxicology of I. rubescens provides updated information for the further development and application in the fields of functional foods and new drug research.

References

• Rabdosia rubescens (Hemsl.) H. Hara: A potent anti-tumor herbal remedy — Botany, phytochemistry, and clinical applications and insights. PubMed / Journal of Ethnopharmacology (2025)
• Chen X et al. Isodon rubescens (Hemls.) Hara.: A Comprehensive Review on Traditional Uses, Phytochemistry, and Pharmacological Activities. Frontiers in Pharmacology / PMC (2022)
• Isodon rubescens (Hemls.) Hara.: A Comprehensive Review on Traditional Uses, Phytochemistry, and Pharmacological Activities. Frontiers in Pharmacology (2022)
• Li X et al. Oridonin: A Review of Its Pharmacology, Pharmacokinetics and Toxicity. Frontiers in Pharmacology / PMC (2021)
• Oridonin: A Review of Its Pharmacology, Pharmacokinetics and Toxicity. Frontiers in Pharmacology (2021)
• Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammasome activity. Nature Communications (2018)
• Genomic and in vivo evidence of synergy of a herbal extract compared to its most active ingredient: Rabdosia rubescens vs. oridonin. PubMed / Experimental and Therapeutic Medicine (2012)
• Phytotherapeutics Oridonin and Ponicidin show Additive Effects Combined with Irradiation in Pancreatic Cancer in Vitro. PMC (2018)
• Isodon rubescens — an overview. ScienceDirect Topics
• Rabdosia rubescens (Hemsl.) H. Hara: A potent anti-tumor herbal remedy — Botany, phytochemistry, and clinical applications and insights. ScienceDirect / Journal of Ethnopharmacology (2024)
• Inhibitory Effects of Rabdosia rubescens in Esophageal Squamous Cell Carcinoma: Network Pharmacology and Experimental Validation. PMC (2022)
• Involvement of Glutathione Depletion in Selective Cytotoxicity of Oridonin to p53-Mutant Esophageal Squamous Carcinoma Cells. PMC / Frontiers in Oncology (2019)
• Isodon rubescens research literature based on Web of Science database for visual analysis: A review. PMC (2025)
• Terahertz spectroscopy study of oridonin and ponicidin in the anticancer Chinese herbal medicine Rabdosia rubescens. PMC (2024)
• Meade-Tollin LC et al. Ponicidin and Oridonin Are Responsible for the Antiangiogenic Activity of Rabdosia rubescens, a Constituent of the Herbal Supplement PC SPES. Journal of Natural Products (2004)
• PC-SPES — Complementary and Alternative Medicine (PDQ®). National Cancer Institute (NCI)
• PC-SPES — Patient Information. National Cancer Institute (NCI)
• Small EJ et al. Clinical and Biologic Activity of an Estrogenic Herbal Combination (PC-SPES) in Prostate Cancer. New England Journal of Medicine (1998)
• Bonham M et al. Molecular Effects of the Herbal Compound PC-SPES: Identification of Activity Pathways in Prostate Carcinoma. Cancer Research (2002)
• Oridonin inhibits aberrant AKT activation in breast cancer. Oncotarget (2018)
• Jaridonin-induced G2/M phase arrest in human esophageal cancer cells is caused by reactive oxygen species-dependent Cdc2-tyr15 phosphorylation. PMC (2016)
• Preliminary study on the mechanism of oridonin-induced apoptosis in human squamous cell oesophageal carcinoma cell line EC9706. PubMed (2014)
• Protective effects of oridonin against cerebral ischemia/reperfusion injury by inhibiting the NLRP3 inflammasome activation. PubMed (2021)
• Oridonin ameliorates acetaminophen-induced acute liver injury through ATF4/PGC-1α pathway. PubMed (2023)
• Oridonin attenuates diclofenac-induced organ damage by suppressing endoplasmic reticulum stress and inflammasome activation. Frontiers in Toxicology (2026)
• Rabdosia rubescens Inhibits CYP7A1 Expression and Induces Autophagy to Reduce Alcohol-Induced Liver Damage in Mice. PMC (2025)
• Comparative analysis of chloroplast genomes reveals phylogenetic relationships and intraspecific variation in the medicinal plant Isodon rubescens. PMC (2022)
• Oridonin attenuates apoptosis and NLRP3 inflammasome activation in IL-4-stimulated human bronchial epithelial cells in an in vitro pediatric asthma model. PubMed (2023)